• Corpus ID: 244714523

The Computational Drug Repositioning without Negative Sampling

@article{Yang2021TheCD,
  title={The Computational Drug Repositioning without Negative Sampling},
  author={Xinxing Yang and Gen-ke Yang and Jian Chu},
  journal={ArXiv},
  year={2021},
  volume={abs/2111.14696}
}
Computational drug repositioning technology is an effective tool to accelerate drug development. Although this technique has been widely used and successful in recent decades, many existing models still suffer from multiple drawbacks such as the massive number of unvalidated drug-disease associations and the inner product. The limitations of these works are mainly due to the following two reasons: firstly, previous works used negative sampling techniques to treat unvalidated drug-disease… 

References

SHOWING 1-10 OF 36 REFERENCES
Additional Neural Matrix Factorization model for computational drug repositioning
TLDR
The proposed ANMF model makes use of drug-drug similarities and disease-disease similarities to enhance the representation information of drugs and diseases in order to overcome the matter of data sparsity and play a role in answering to the major challenge in drug repositioning.
Biomedical data and computational models for drug repositioning: a comprehensive review
TLDR
This review summarizes the available biomedical data and public databases related to drugs, diseases and targets and discusses existing drug repositioning approaches and group them based on their underlying computational models consisting of classical machine learning, network propagation, matrix factorization and completion, and deep learning based models.
Computational drug repositioning using low-rank matrix approximation and randomized algorithms
TLDR
A drug repositioning recommendation system (DRRS) to predict novel drug indications by integrating related data sources and validated information of drugs and diseases is proposed and improves the prediction accuracy compared with the other state-of-the-art approaches.
Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm
TLDR
A novel computational method named MBiRW is proposed, which utilizes some comprehensive similarity measures and Bi-Random walk (BiRW) algorithm to identify potential novel indications for a given drug, and outperforms several recent computational drug repositioning approaches.
iDrug: Integration of drug repositioning and drug-target prediction via cross-network embedding
TLDR
This paper presents a novel approach called iDrug, which seamlessly integrates drug repositioning and drug-target prediction into one coherent model via cross-network embedding and provides a principled way to transfer knowledge from these two domains and to enhance prediction performance for both tasks.
The Neural Metric Factorization for Computational Drug Repositioning
TLDR
A neural metric factorization model for computational drug repositioning (NMFDR) is proposed and a generalized Euclidean distance is proposed to represent the association between drugs and diseases to compensate for the shortcomings of the inner product operation.
Drug repositioning: re-investigating existing drugs for new therapeutic indications.
TLDR
Challenges in clinical trials and intellectual property issues may be encountered during the repositioning process, however, such initiatives not only add value to the portfolio of pharmaceutical companies but also provide an opportunity for academia and government laboratories to develop new and innovative uses of existing drugs for infectious and neglected diseases.
Computational drug repositioning based on the relationships between substructure-indication
TLDR
This article integrated the features of chemical-genomics (substructure-domain) and pharmaco- genomics (domain-indication) based on the assumption that drug-target interactions are mediated by the substructures of drugs and the domains of proteins to identify the relationships between substructure-indicated and establish a drug-subst structure-indications network for predicting all therapeutic effects of tested drugs through only information on the substructure of drugs.
Computational drug repositioning based on multi-similarities bilinear matrix factorization
TLDR
A multi-similarities bilinear matrix factorization (MSBMF) method to predict promising drug-associated indications for existing and novel drugs is proposed and numerically solve the MSBMF model by an efficient alternating direction method of multipliers algorithm.
...
1
2
3
4
...